Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

People attending a football match will be asked to sign up to a stem cell register in the hope of finding a donor for a local ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology. Cutaneous T ...

"The complete response rate, consistent treatment response and safety profile across multiple clinical studies to date with HyBryte™ has been exciting to see," noted Dr. Kim, Principal ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology.

Despite the statistically significant result achieved in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that the ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

Cutaneous T-cell lymphoma is a group of rare blood cancers that affects the skin. Nine patients have been enrolled and treated with HyBryte over up to 54 weeks. Also Read: Soligenix Kickstarts ...

The next donor recruitment drives for the Marshall's Match campaign are being held this weekend - with one taking place at ...

Soligenix, Inc. (NASDAQ: SNGX) decreased in price early Tuesday, as the late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...